| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/11/2012 | CA2611901C Spray-drying process for producing a dry carnitine powder or granulate |
| 12/11/2012 | CA2579197C New double salts of (-)-hydroxycitric acid and a process for preparing the same |
| 12/11/2012 | CA2576144C Sigma receptor inhibitors |
| 12/11/2012 | CA2571722C Phenyl derivatives comprising an acetylene group |
| 12/11/2012 | CA2570942C Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament |
| 12/11/2012 | CA2565237C Quinoxaline inhibitors of hedgehog signalling |
| 12/11/2012 | CA2563975C Compounds and compositions as cathepsin s inhibitors |
| 12/11/2012 | CA2563461C Pyrazole phenyl derivatives as ppar activators |
| 12/11/2012 | CA2562539C Substituted cyclohexylcarboxylic acid derivatives |
| 12/11/2012 | CA2561975C Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists |
| 12/11/2012 | CA2560010C Antimicrobial compositions |
| 12/11/2012 | CA2559476C Treatment of fibrosis using fxr ligands |
| 12/11/2012 | CA2557789C Pyrazolyl indolyl derivatives as ppar activators |
| 12/11/2012 | CA2553705C 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
| 12/11/2012 | CA2552679C Tulobuterol adhesive patch |
| 12/11/2012 | CA2549628C Fused pyrrolocarbazoles and methods for the preparation thereof |
| 12/11/2012 | CA2549627C Novel fused pyrrolocarbazoles |
| 12/11/2012 | CA2541928C Method for the production of amino crotonyl compounds |
| 12/11/2012 | CA2535704C Aminopropanol derivatives |
| 12/11/2012 | CA2532489C Infant or follow-on formula |
| 12/11/2012 | CA2515780C Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 12/11/2012 | CA2513807C Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| 12/11/2012 | CA2490580C Selective estrogen receptor modulators containing a naphthalene group |
| 12/11/2012 | CA2484632C Processes for forming a drug delivery device |
| 12/11/2012 | CA2483890C Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| 12/11/2012 | CA2477516C Pharmaceutical formulation comprising melatonin |
| 12/11/2012 | CA2451980C 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune disorders |
| 12/11/2012 | CA2420061C Pharmaceutical composition for depot administration of rotigotine |
| 12/11/2012 | CA2328996C Implants for administering substances and methods of producing implants |
| 12/11/2012 | CA2202519C Cloning, expression and characterization of a new form of phosphatidylinositol-3-kinase |
| 12/09/2012 | CA2778850A1 New co-crystals of agomelatine, their preparation process and the pharmaceutical compositions in which they are found |
| 12/08/2012 | CA2779045A1 Synthesis process and crystalline form of benzamide 4-{3-¬cis-hexahydrocyclopenta¬c|pyrrol-2(1h)-yl|propoxy} hydrochloride as well as the pharmaceutical compositions in which it is found |
| 12/06/2012 | WO2012167281A2 Clinical application utilizing genetic data for effective medication management |
| 12/06/2012 | WO2012167261A2 Compositions and methods for treating and preventing neointimal stenosis |
| 12/06/2012 | WO2012167255A1 Anticancer prodrug therapies |
| 12/06/2012 | WO2012167243A1 Compositions and methods of treatment for obesity |
| 12/06/2012 | WO2012167237A2 Compounds having antiparasitic or anti-infectious activity |
| 12/06/2012 | WO2012167236A1 Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
| 12/06/2012 | WO2012167226A2 Method, composition, and articles for improving joint lubrication |
| 12/06/2012 | WO2012167214A1 Compositions and methods for transport across the blood brain barrier |
| 12/06/2012 | WO2012167212A2 Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| 12/06/2012 | WO2012167133A2 Inhibitors of anandamide transport and their therapeutic uses |
| 12/06/2012 | WO2012167122A1 Compounds, compositions and methods for treating oxidative dna damage disorders |
| 12/06/2012 | WO2012167101A1 Ovarian cancer stem cells and methods of isolation and uses thereof |
| 12/06/2012 | WO2012167099A1 Biomarkers and therapy for cancer |
| 12/06/2012 | WO2012167092A2 Uses of and methods of treatment with cystathionine |
| 12/06/2012 | WO2012167081A1 Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom |
| 12/06/2012 | WO2012167061A1 OPSONIZED β-GLUCAN PREPARATIONS AND METHODS |
| 12/06/2012 | WO2012167053A1 Novel immune system modulators |
| 12/06/2012 | WO2012167046A1 Novel immune system modulators |
| 12/06/2012 | WO2012167018A1 Targeted delivery of retinoid compounds to the sebaceous glands |
| 12/06/2012 | WO2012166998A1 Compositions for sequential administration of opioid receptor agonists |
| 12/06/2012 | WO2012166991A1 S-nitrosylation of glucosylating toxins and uses therefor |
| 12/06/2012 | WO2012166987A2 Liphagal enantiomers and their derivatives and precursors, and enantioselective methods of making the same |
| 12/06/2012 | WO2012166983A1 Tricyclic inhibitors of poly(adp-ribose)polymerase |
| 12/06/2012 | WO2012166951A1 Novel glp-1 receptor stabilizers and modulators |
| 12/06/2012 | WO2012166949A1 Silicate prodrugs and nanoparticles |
| 12/06/2012 | WO2012166936A1 Oxidatively-stabilized fats containing very long-chain omega-3 polyunsaturated fatty acids |
| 12/06/2012 | WO2012166934A1 Methods and compositions for the treatment of pain |
| 12/06/2012 | WO2012166923A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 12/06/2012 | WO2012166909A1 Compositions and methods for treating breathing control disorders or diseases |
| 12/06/2012 | WO2012166891A2 Mu-opioid receptor binding compounds |
| 12/06/2012 | WO2012166862A1 Compositions and methods for treating alzheimer's disease |
| 12/06/2012 | WO2012166859A2 Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| 12/06/2012 | WO2012166778A2 Conjugates of nitroimidazoles and their use as chemotherapeutic agents |
| 12/06/2012 | WO2012166716A2 Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
| 12/06/2012 | WO2012166706A2 Supramolecular nanofibers and hydrogels based on oligopeptides functionalized with nucleobases |
| 12/06/2012 | WO2012166705A2 Supramolecular nanofibers and hydrogels based on amino acid-nucleobase-glycoside conjugates |
| 12/06/2012 | WO2012166665A2 Broad spectrum antibiotics |
| 12/06/2012 | WO2012166658A1 Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| 12/06/2012 | WO2012166654A1 Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
| 12/06/2012 | WO2012166645A1 Prodrugs of azacitidine 5' -diphosphate |
| 12/06/2012 | WO2012166614A2 Thiocarbamate and sulfonamide hydroxamate inhibitors of insulin-degrading enzyme |
| 12/06/2012 | WO2012166611A2 Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| 12/06/2012 | WO2012166586A1 SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF |
| 12/06/2012 | WO2012166560A1 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| 12/06/2012 | WO2012166559A1 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| 12/06/2012 | WO2012166544A1 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders |
| 12/06/2012 | WO2012166534A1 Method of determining vasoreactivity using inhaled nitric oxide |
| 12/06/2012 | WO2012166533A1 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders |
| 12/06/2012 | WO2012166463A2 Aminooxazole inhibitors of cyclin dependent kinases |
| 12/06/2012 | WO2012166459A1 Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
| 12/06/2012 | WO2012166458A1 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use |
| 12/06/2012 | WO2012166420A1 Phosphoric acid salts of sitagliptin |
| 12/06/2012 | WO2012166415A1 Heterocyclic autotaxin inhibitors and uses thereof |
| 12/06/2012 | WO2012166390A1 Neprilysin inhibitors |
| 12/06/2012 | WO2012166387A1 Neprilysin inhibitors |
| 12/06/2012 | WO2012166151A1 Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| 12/06/2012 | WO2012166070A1 Dry powder formulation with improved flow characteristics |
| 12/06/2012 | WO2012166008A1 Combination for treatment of diabetes mellitus |
| 12/06/2012 | WO2012165995A1 Photodynamic treatment method for malignant tumors |
| 12/06/2012 | WO2012165985A1 An analgesic pharmaceutical composition for oral administration |
| 12/06/2012 | WO2012165984A1 Clenbuterol for use in treatment of autism |
| 12/06/2012 | WO2012165981A1 Novel hybrid cholinesterase inhibitors |
| 12/06/2012 | WO2012165956A1 N,n-substituted guanidine compound |
| 12/06/2012 | WO2012165917A1 Stable liquid formulation of etanercept |
| 12/06/2012 | WO2012165914A2 Novel diphenylmethane derivatives as sglt2 inhibitors |
| 12/06/2012 | WO2012165854A2 Long interfering dsrna simultaneously inducing an immune reaction and the inhibition of the expression of target genes |
| 12/06/2012 | WO2012165810A2 Pharmaceutical composition containing wogonin as an active ingredient for preventing or treating asthma |
| 12/06/2012 | WO2012165736A1 Remedy for gastritis and gastric ulcer |